购物车
- 全部删除
- 您的购物车当前为空
AZ 12799734 是一种具有口服活性、选择性和有效性的 TGFBR1和 ALK5 双重抑制剂,对 BMP 和 TGFβ 有抑制作用,可用于研究肿瘤。
为众多的药物研发团队赋能,
让新药发现更简单!
AZ 12799734 是一种具有口服活性、选择性和有效性的 TGFBR1和 ALK5 双重抑制剂,对 BMP 和 TGFβ 有抑制作用,可用于研究肿瘤。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 483 | 现货 | |
5 mg | ¥ 1,160 | 现货 | |
10 mg | ¥ 1,860 | 现货 | |
25 mg | ¥ 3,950 | 现货 | |
50 mg | ¥ 5,850 | 现货 | |
100 mg | ¥ 7,890 | 现货 | |
200 mg | ¥ 10,600 | 现货 |
产品描述 | AZ 12799734 is an orally active, selective and potent dual inhibitor of TGFBR1 and ALK5 with inhibitory effects on BMP and TGFβ for the study of tumours. |
靶点活性 | ALK6:0.017 μM (Kd), TGFβRI:47 nM, ALK4:1 μM (Kd), ALK1:7.1 μM (Kd), BMPR1A:40 μM (Kd), ALK5:0.74 μM (Kd), ACVR1:6.2 μM (Kd) |
体外活性 | Inhibiting ligand-activated SMAD3/4 transcription, AZ12799734[2]. AZ12799734 (10 nM; 24 h) inhibits phosphorylation of both SMAD1 and SMAD2[2]. AZ12799734 (500 nM; 36 h) inhibits TGFβ-induced migration in HaCaT epithelial cells[2]. |
体内活性 | Inducing histopathologic heart valve lesions in rats, AZ12799734 is administered orally at doses ranging from 0 to 400 mg/kg/day for 3-7 days[1]. At a single oral dose of 50 mg/kg, AZ12799734 shows total and free pharmacokinetic (PK) levels in nude mice over time, exceeding the in vitro IC50 of 0.01885 μM[2]. |
别名 | AZ12799734 |
分子量 | 370.43 |
分子式 | C18H18N4O3S |
CAS No. | 1117684-36-2 |
Smiles | O(C=1C=C(NC2=CC=C(S(N)(=O)=O)C=C2)N=CC1)C3=C(C)N=C(C)C=C3 |
存储 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 80 mg/mL (215.97 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
评论内容